Viewing nowCombinationVR Tablet 5/80 mg
Rosuvastatin Calcium 5.2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.

MFDS item code 202003037 · Approved 2020.04.24 · Insurance code 645906930
Treatment of hypertension and heart failure; inhibition of lipid disorders and atherosclerosis; reduction of cardiovascular and mortality risk
This medication is used for patients who require simultaneous administration of both valsartan and rosuvastatin. Valsartan is primarily used to treat essential hypertension, heart failure, especially in patients intolerant to ACE inhibitors, and to reduce the risk of mortality after myocardial infarction. Meanwhile, rosuvastatin is prescribed as an adjunct when dietary measures and exercise do not adequately control hypercholesterolemia and mixed hyperlipidemia. It is also beneficial for patients with homozygous familial hypercholesterolemia and dysbetalipoproteinemia. Furthermore, it is effective in reducing the risk of stroke, myocardial infarction, and revascularization in patients with elevated high-sensitivity C-reactive protein levels or other cardiovascular risk factors. In summary, this medication is used for managing hypertension and heart failure, treating various forms of hyperlipidemia, and reducing the risk of cardiovascular diseases.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily, or a diuretic may be administered concomitantly. If further blood pressure reduction is required, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this medicine at 40 mg once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, initiate treatment with this medicine at 40 mg once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consideration should be given to reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, the dose may be increased according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher. However, as there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine to these patients. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response. The dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Essential hypertension — Safety and efficacy have not been established in children and adolescents under 18 years of age. Heart failure — Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication and must employ appropriate contraceptive measures before administration. It is not safe for patients with severely impaired liver function or certain liver diseases to take this medication. Patients with a history of muscle disorders or those prone to myopathy should also take caution when using this medication, and high doses are contraindicated. Elderly patients or those with elevated serum potassium levels, and patients with mild to moderate liver impairment should be closely monitored while taking this medication. Special caution is required for patients with heart conditions, diminished kidney function, or those scheduled for surgery. Symptoms such as muscle pain, weakness, or cramps should be reported to healthcare professionals immediately, and muscle enzyme tests should be performed if necessary. There may be interactions when taken with other medications, so patients should inform their healthcare providers of any other medications they are taking. This medication can lower blood pressure, so patients should be cautious of symptoms of hypotension or dizziness, particularly when driving or operating machinery. Regular monitoring of liver and kidney function tests may be necessary, so tests should be conducted as directed by healthcare professionals. Safety and efficacy have not been established for children and adolescents, so it is advised not to administer this medication to those under 18 years. In the case of overdose, immediate medical attention should be sought, as self-treatment can be dangerous. This medication should be kept out of reach of children and should not be transferred to other containers.
Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased blood levels of liver amino transferases (AST, ALT), increased blood creatine phosphokinase, increased blood potassium, increased gamma-glutamyl transferase, musculoskeletal rigidity, limb pain, sensory impairment, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetes complications, leg fractures, spinal fractures, fractures, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, herniated disc, hemoptysis, sputum disorders, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, stomatitis, gastritis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, worsened hypertension, neck/shoulder pain, toe fractures, osteomyelitis, skin infection, unspecified skin inflammation, localized skin reaction, palpitations, worsened angina, auditory changes, overactive bladder, increased blood creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal discomfort, arthralgia, hypotension, orthostatic dizziness, orthostatic hypotension, kidney function impairment, hyperkalemia, drowsiness, atrial fibrillation, loss of appetite, weakness, vascular edema, erythema, itching, serum sickness, vasculitis, hepatitis, arrhythmia, intestinal vascular edema, interstitial pneumonia, hypoglycemia, shock, syncope, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased red blood cell volume, decreased hemoglobin, edema, constipation, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, weakness, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, oculobulbar weakness
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a container that blocks light. Additionally, it is best stored at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication’s effectiveness.
Yellow, round, film-coated tablet
30 tablets/box [(10 tablets/PTP)*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 5.2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Medika Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.